Christopher Bair, MD
Retina Specialist · Hermitage, PANPI 1245763390
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (55.2%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. Genentech USA, Inc. accounts for 65.4% of it on its own, with 14 other manufacturers making up the rest. Reporting peaked in 2023 at $6,233 and has fallen 82.3% since, to $1,103 in 2025.
Across 107 payments — averaging $83.48 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Genentech USA, Inc.$6K
- Regeneron Healthcare Solutions, Inc.$713
- Apellis Pharmaceuticals, Inc.$642
- Astellas Pharma US Inc$376
- AbbVie$322
- Alcon$251
- plus $790 from 9 others
What the payments were for
- Consulting fees$4,93555%
- Travel & lodging$5126%
- Food & beverage$3,48639%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Genentech USA, Inc. | 14 | $5,838 |
| Regeneron Healthcare Solutions, Inc. | 26 | $713 |
| Apellis Pharmaceuticals, Inc. | 19 | $642 |
| Astellas Pharma US Inc | 11 | $376 |
| AbbVie(2 entities) | 10 | $322 |
| Alcon | 5 | $251 |
| Alimera Sciences, Inc. | 7 | $209 |
| Oculus Surgical Inc. | 1 | $162 |
| Sight Sciences, Inc. | 1 | $105 |
| Harrow Eye, LLC | 3 | $104 |
| ANI Pharmaceuticals, Inc. | 4 | $76 |
| Ocular Therapeutix, Inc. | 3 | $53 |
| Eyepoint US, Inc. | 1 | $35 |
| Glaukos Corporation | 1 | $29 |
| Bausch & Lomb Americas Inc. | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- VABYSMO$5,646
- Syfovre$368
- Izervay$140
- EYLEA HD$135
- EYLEA$111
- AcrySof IQ VIVITY IOL$106
- OMNI(R) SURGICAL SYSTEM (US)$105
How this compares
$8,932 in reported general payments places this provider in the 85th percentile of 43 retina specialist providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Prednisolone Acetate | 195 | $7,928 |
| Ketorolac Tromethamine | 101 | $2,610 |
| Brimonidine Tartrate | 46 | $1,163 |
| Atropine Sulfate | 25 | $915 |
| Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha | 52 | $540 |
| Ofloxacin | 35 | $458 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 43 | $415 |
| Ciprofloxacin Hcl | 28 | $351 |
| Latanoprost | 24 | $291 |
| Diclofenac Sodium | 18 | $219 |
| Tobramycin | 21 | $161 |
Paid to pharmacies, not to this prescriber.
Other retina specialist in Hermitage
- Joshua GreenePhiladelphia$394K
- Jay ChhablaniPittsburgh$70K
- Sachin PatelPottsville$17K
- Brian VanderbeekPhiladelphia$14K
- Thucanh MultererFogelsville$9K
- Albert MaguirePhiladelphia$9K
- Hugo LinaresPhiladelphia$7K
- Moiz CarimWyomissing$6K
- Salman PorbandarwallaLancaster$6K
- Benjamin KimPhiladelphia$5K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.